RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
 Clinical Trials
 Infectious Diseases
  Anorexia Nervosa
   Panic Disorders
   Social Phobia
  Child Psychiatry
  Forensic Psychiatry
  Mood Disorders
  Peri-Natal Psychiatry
  Personality Disorders
  Sleep Disorders
  Substance Abuse
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM
Research Article
PTSD Channel

subscribe to PTSD newsletter
Latest Research : Psychiatry : Anxiety : PTSD

   EMAIL   |   PRINT
Guanfacine in PTSD is no more effective than placebo

Dec 4, 2006 - 12:39:58 PM , Reviewed by: Himanshu Tyagi
“These results do not support the use of alpha 2 agonists in veterans with chronic PTSD.”

[RxPG] Guanfacine, a medication commonly prescribed to alleviate symptoms of post-traumatic stress disorder, is no more effective than a placebo, according to a study led by researchers at the San Francisco VA Medical Center.

“There was no benefit at all, and there were several adverse side effects,” says lead author Thomas Neylan, MD, medical director of the PTSD treatment program at SFVAMC. “People with symptoms of PTSD should probably stay away from this drug and others of its type.”

Guanfacine belongs to a class of medications known as alpha-2 agonists, which lower the brain’s supply of the neurotransmitter norepinephrine. Neurotransmitters are chemicals that transmit electrical signals between nerve cells. They are responsible for many aspects of behavior.

“Norepinephrine is released in the brain during states of excited arousal, and PTSD is associated with that state – patients startle easily, have trouble sleeping, and are hypervigilant and anxious,” explains Neylan, who is also an associate professor of psychiatry at the University of California, San Francisco.

Guanfacine and clonidine, another alpha-2 agonist, are commonly prescribed for PTSD symptoms. “There are at least 20 peer-reviewed articles published in the field of PTSD that recommend drugs which lower norepinephrine,” Neylan says. “However, ours was the first randomized, controlled study of alpha-2 agonists for symptoms of PTSD.”

The double-blind study compared the effects of guanfacine and an identical looking placebo pill on 63 male and female veterans at four VA medical centers in California and Hawaii. Twenty-nine participants were randomly assigned to take weekly doses of the drug, and 34 were assigned the placebo, for eight weeks.

At the end of the study, the effect of guanfacine on PTSD symptoms was “zero,” and there were no differences between men and women or older versus younger veterans. In addition, the subjects who took guanfacine had significantly more somnolence, lightheadedness, and dry mouth than those who took placebo.

The study authors conclude, “These results do not support the use of alpha 2 agonists in veterans with chronic PTSD.”

Neylan speculates that instead of lowering the overall level of norepinephrine, a more effective approach might be to inhibit the ability of brain cells to respond to the neurotransmitter. He notes that this is the action of prazosin, a blood pressure medication that has been found by other researchers to decrease the incidence of nightmares in combat veterans with PTSD.

Publication: The study appears in the December 1, 2006 issue of the American Journal of Psychiatry.
On the web: www.ucsf.edu 

Funding information and declaration of competing interests: The study was funded by support from the Department of Veterans Affairs.

Advertise in this space for $10 per month. Contact us today.

Related PTSD News
Deep brain mapping to isolate evidence of Gulf War syndrome
Guanfacine in PTSD is no more effective than placebo
Men, women respond to trauma differently
Mental illnesses double up in Katrina survivors
Psychological debriefing after trauma does not reduce PTSD
Tsunami Survivors Face Increased Risk of Mental Disorders
Substantial burden of PTSD among people after disasters
PTSD after Nairobi and Oklahoma terrorist bombings - Study
Life events generate more symptoms of PTSD than traumatic events
9/11 Babies Have Markers of Post Traumatic Stress Disorder

Subscribe to PTSD Newsletter

Enter your email address:

 Additional information about the news article
Study co-authors were Maryann Lenoci, MA, and Kristin W. Franklin, PhD, of SFVAMC; Thomas J. Metzler, MA, of UCSF and SFVAMC; Clare Henn-Haase, PsyD, of SFVAMC; Robert W. Hierholzer, MD, of UCSF and Fresno VA Medical Center, Fresno, Calif.; Steven E. Lindley, MD, PhD, of Stanford University and Palo Alto VA Medical Center, Palo Alto, Calif.; Christian Otte, MD, of UCSF, SFVAMC, and University Hospital Hamburg-Eppendorf, Germany; Frank B. Schoenfeld, MD, of UCSF and SFVAMC; Jerome A. Yesavage, MD, of Stanford University and PAVAMC; and Charles R. Marmar, MD, of SFVAMC and UCSF.

SFVAMC has the largest medical research program in the national VA system, with more than 200 research scientists, all of whom are faculty members at UCSF.

UCSF is a leading university that advances health worldwide by conducting advanced biomedical research, educating graduate students in the life sciences and health professions, and providing complex patient care.
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)